Overview

Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

This is a phase 1, open-label, randomized pharmacokinetic and safety study in healthy adult subjects, who will undergo bronchoscopy and bronchoalveolar lavage (BAL) after receiving seven (7) doses of 1.0 mg/kg IV TP-434.

Phase:

Phase 1

Details

Lead Sponsor:

Tetraphase Pharmaceuticals, Inc.

Collaborator:

Department of Health and Human Services